Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zai Lab Ltd ( (HK:9688) ) just unveiled an announcement.
Zai Lab Ltd announced the grant of 3,300 Restricted Share Units (RSUs) to three employees under its 2024 Equity Incentive Plan. This move is intended to recognize and reward the contributions of these employees and to provide additional incentives for their continued success with the company. The RSUs will vest over four years, with no performance targets or clawback mechanisms attached, aligning with the company’s market-competitive practices. This grant reflects Zai Lab’s commitment to fostering employee engagement and promoting business success.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Ltd is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative medicines. The company operates primarily in the healthcare industry, offering products and services aimed at addressing significant unmet medical needs.
Average Trading Volume: 16,051,317
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.89B
See more data about 9688 stock on TipRanks’ Stock Analysis page.